MIRM insider transaction filings
Mirum Pharmaceuticals, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-15. Screen MIRM transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 10 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 19 legs across 10 filings by 3 insiders — 136,163 shares, $14,159,114 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
- Largest priced transaction: sale of 40,000 shares @ $100.00 ($4,000,000) by Howe Jolanda, filed 2026-08-19.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Peetz Christopher — CHIEF EXECUTIVE OFFICER, Director | 3 | — | 9 legs · 70,000 sh · $7,384,185 | 6 |
| Howe Jolanda — SVP, GLOBAL CONTROLLER | 4 | — | 4 legs · 45,219 sh · $4,586,054 | 2 |
| BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER | 3 | — | 6 legs · 20,944 sh · $2,188,876 | 2 |
Recent Form 4 filings — Mirum Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER | Option exercise (M): 18,333 · Sale (S): 9,943 @ $98.37 · Option exercise (M): 18,333 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | Peetz Christopher — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 30,000 @ $2.94 · Sale (S): 8,312 @ $98.08 · Sale (S): 21,688 @ $98.91 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | Howe Jolanda — SVP, GLOBAL CONTROLLER | Sale (S): 658 @ $100 | EDGAR |
| 2026-08-19 | 4 | Howe Jolanda — SVP, GLOBAL CONTROLLER | Option exercise (M): 40,000 @ $6.27 · Sale (S): 40,000 @ $100 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER | Sale (S): 6,001 @ $99.90 | EDGAR |
| 2026-08-11 | 4 | Peetz Christopher — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 20,000 @ $2.94 · Sale (S): 11,683 @ $98.51 · Sale (S): 6,017 @ $99.25 · Sale (S): 2,300 @ $100.14 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Howe Jolanda — SVP, GLOBAL CONTROLLER | Sale (S): 1,840 @ $105.29 | EDGAR |
| 2026-07-08 | 4 | Peetz Christopher — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 20,000 @ $2.94 · Sale (S): 12,134 @ $121.65 · Sale (S): 4,181 @ $122.34 · Sale (S): 1,975 @ $123.74 · Sale (S): 1,710 @ $124.79 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER | Sale (S): 3,124 @ $121.67 · Sale (S): 1,048 @ $122.43 · Sale (S): 528 @ $123.84 · Sale (S): 300 @ $124.94 | EDGAR |
| 2026-07-02 | 4 | Howe Jolanda — SVP, GLOBAL CONTROLLER | Sale (S): 2,721 @ $120 | EDGAR |
| 2026-06-18 | 4 | Howe Jolanda — SVP, GLOBAL CONTROLLER | Sale (S): 2,594 @ $101.95 | EDGAR |
| 2026-06-17 | 4 | Cardon Lon — Director | Grant/award (A): 3,772 (derivative) @ $0 · Grant/award (A): 1,980 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Fairey William — Director | Grant/award (A): 3,772 (derivative) @ $0 · Grant/award (A): 1,980 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Ramasastry Saira — Director | Grant/award (A): 3,772 (derivative) @ $0 · Grant/award (A): 1,980 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Fischer Laurent — Director | Grant/award (A): 3,772 (derivative) @ $0 · Grant/award (A): 1,980 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Brege Laura — Director | Grant/award (A): 3,772 (derivative) @ $0 · Grant/award (A): 1,980 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Heron Patrick J — Director | Grant/award (A): 3,772 (derivative) @ $0 · Grant/award (A): 1,980 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Walbert Timothy P — Director | Grant/award (A): 3,772 (derivative) @ $0 · Grant/award (A): 1,980 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | GREY MICHAEL G — Director | Grant/award (A): 3,772 (derivative) @ $0 · Grant/award (A): 1,980 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER | Sale (S): 2,258 @ $92.84 · Sale (S): 1,175 @ $93.95 · Sale (S): 1,567 @ $95.12 · Option exercise (M): 2,393 @ $26.49 · Option exercise (M): 2,393 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Radovich Peter — PRESIDENT AND COO | Option exercise (M): 16,988 @ $19.19 · Option exercise (M): 16,988 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Cardon Lon — Director | Option exercise (M): 3,977 · Option exercise (M): 3,977 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Peetz Christopher — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 30,000 @ $2.94 · Sale (S): 2,602 @ $94.64 · Sale (S): 16,595 @ $95.34 · Sale (S): 6,926 @ $96.15 · Sale (S): 1,973 @ $97.56 · Sale (S): 1,021 @ $98.20 · +2 more | EDGAR |
| 2026-06-02 | 4 | Ramasastry Saira — Director | Option exercise (M): 3,977 · Sale (S): 3,977 @ $100 · Option exercise (M): 3,977 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Fischer Laurent — Director | Option exercise (M): 3,977 · Option exercise (M): 3,977 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Walbert Timothy P — Director | Option exercise (M): 3,977 · Option exercise (M): 3,977 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Ramasastry Saira — Director | Option exercise (M): 2,000 @ $23.51 · Sale (S): 2,000 @ $109.47 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-04-16 | 4 | Ramasastry Saira — Director | Option exercise (M): 2,000 @ $23.51 · Sale (S): 2,000 @ $96.90 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Howe Jolanda — SVP, GLOBAL CONTROLLER | Option exercise (M): 2,658 · Option exercise (M): 6,000 · Sale (S): 4,732 @ $91.98 · Option exercise (M): 2,658 (derivative) @ $0 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Quan Joanne — CHIEF MEDICAL OFFICER | Option exercise (M): 13,334 · Sale (S): 7,287 @ $91.98 · Option exercise (M): 13,334 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Radovich Peter — PRESIDENT AND COO | Option exercise (M): 7,220 · Option exercise (M): 23,000 · Sale (S): 16,515 @ $91.98 · Option exercise (M): 7,220 (derivative) @ $0 · Option exercise (M): 23,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Peetz Christopher — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 25,000 · Option exercise (M): 50,000 · Sale (S): 40,985 @ $91.98 · Option exercise (M): 25,000 (derivative) @ $0 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Ramasastry Saira — Director | Option exercise (M): 2,000 @ $23.51 · Sale (S): 2,000 @ $90.76 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER | Option exercise (M): 13,334 · Sale (S): 7,287 @ $91.98 · Option exercise (M): 13,334 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Radovich Peter — PRESIDENT AND COO | Option exercise (M): 5,912 @ $15.87 · Option exercise (M): 5,912 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Ramasastry Saira — Director | Option exercise (M): 2,000 @ $23.51 · Sale (S): 2,000 @ $102.09 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Howe Jolanda — SVP, GLOBAL CONTROLLER | Option exercise (M): 1,771 · Sale (S): 968 @ $103.30 · Option exercise (M): 1,771 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Radovich Peter — PRESIDENT AND COO | Sale (S): 2,631 @ $103.30 | EDGAR |
| 2026-02-03 | 4 | Peetz Christopher — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 9,108 @ $103.30 | EDGAR |
| 2026-01-30 | 4 | Howe Jolanda — SVP, GLOBAL CONTROLLER | Grant/award (A): 7,680 (derivative) @ $0 · Grant/award (A): 4,970 (derivative) @ $0 · Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Quan Joanne — CHIEF MEDICAL OFFICER | Grant/award (A): 18,140 (derivative) @ $0 · Grant/award (A): 11,760 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Radovich Peter — PRESIDENT AND COO | Grant/award (A): 25,120 (derivative) @ $0 · Grant/award (A): 16,280 (derivative) @ $0 · Grant/award (A): 34,500 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Peetz Christopher — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 67,000 (derivative) @ $0 · Grant/award (A): 43,500 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER | Grant/award (A): 18,140 (derivative) @ $0 · Grant/award (A): 11,760 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Howe Jolanda — SVP, GLOBAL CONTROLLER | Option exercise (M): 1,500 · Sale (S): 842 @ $96.19 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Radovich Peter — PRESIDENT AND COO | Option exercise (M): 5,750 · Sale (S): 3,143 @ $96.19 · Option exercise (M): 5,750 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Peetz Christopher — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 12,500 · Sale (S): 6,831 @ $96.19 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Heron Patrick J — Director | Other (J): 159,277 · Purchase (P): 131,425 @ $68.48 | EDGAR |
| 2026-01-27 | 4 | BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER | Option exercise (M): 2,667 · Sale (S): 1,053 @ $96.19 · Option exercise (M): 2,667 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | BJERKHOLT ERIC — CHIEF FINANCIAL OFFICER | Option exercise (M): 3,334 · Sale (S): 1,421 @ $93.33 · Option exercise (M): 3,334 (derivative) @ $0 | EDGAR |
Recent 8-K events — Mirum Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-04-27 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-04-08 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-26 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MIRM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →